| First Author | Tang Q | Year | 2024 |
| Journal | Biochem Pharmacol | Volume | 221 |
| Pages | 116039 | PubMed ID | 38301966 |
| Mgi Jnum | J:345705 | Mgi Id | MGI:7595157 |
| Doi | 10.1016/j.bcp.2024.116039 | Citation | Tang Q, et al. (2024) FGF1(DeltaHBS) ameliorates retinal inflammation via suppressing TSPO signal in a type 2 diabetes mouse model. Biochem Pharmacol 221:116039 |
| abstractText | Translocator protein (18 kDa) (TSPO) plays an important role in retinal neuroinflammation in the early stage of diabetic retinopathy (DR). Studies have found that a FGF1 variant (FGF1(DeltaHBS)) with reduced proliferative potency exerts excellent anti-inflammatory effects and potential therapeutic value for diabetic complications. In this study, intravitreal injection of FGF1(DeltaHBS) was administrated every week for one month in db/db mice, which are genetically predisposed to develop type 2 diabetes mellitus and early retinopathy. Changes in retinal function and structure in the animal models were detected by electrophysiology (ERG) and optical tomography coherence (OCT). TSPO expression and retinal inflammation were analyzed by immunofluorescence, Western blot and real-time qPCR. In the retina of T2D (db/db) mice, FGF1 was significantly down-regulated while FGFR1 was up-regulated (both p < 0.05). TSPO and retinal inflammatory factors were all up-regulated. TSPO and FGFR1 were mainly co-stained in the inner retina. After FGF1(DeltaHBS) treatment, ERG showed that the total amplitude of dark-adapted b-wave and oscillating potentials (Ops) was significantly improved, and OCT showed that the thickness of the retina around the optical nerve head was significantly preserved in T2D mice (all p < 0.05). The TSPO signal was significantly suppressed by FGF1(DeltaHBS). The activation of NF-kappaB p65 and the expression of inflammatory factors such as TNF-alpha, IL-1beta, IL-6, COX-2, MIP-1alpha, and iNOS were all significantly down-regulated (all p < 0.05). Collectively, our current data demonstrated that intravitreal FGF1(DeltaHBS) treatment can effectively inhibit retinal inflammation via suppressing TSPO signal and to preserve retinal function and structure in a T2D mouse model. |
